Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020785513> ?p ?o ?g. }
- W3020785513 abstract "Abstract Background Increasing evidence has revealed a close correlation between cancerous inhibitor of protein phosphatase 2A (CIP2A) and cancer progression. CIP2A has been shown to participate in diverse biological processes, such as development, tumorigenic transformation and chemoresistance. However, the functions of CIP2A in colorectal cancer (CRC) and its underlying mechanisms of action are not yet completely understood. The purpose of this study was to explore its clinical significance, function and relevant pathways in CRC. Methods Quantitative RT-PCR (qRT-PCR), immunohistochemistry (IHC), western blotting and enzyme-linked immunosorbent assay (ELISA) were used to identify the expression of CIP2A in CRC tissues, sera and CRC cell lines. The association between the expressions of CIP2A and patient survival was analyzed using the Kaplan-Meier curves. Additionally, the functional role of CIP2A in the cell lines was identified through small interfering RNA (siRNA)-mediated depletion of the protein followed by analyses of proliferation and xenograft growth in vivo using short hairpin (sh) RNAs. Effects of the C-myc inhibitor 10,058-F4 on the expressions of C-myc, and CIP2A in CRC cell lines and its potential mechanisms of action were investigated. Finally, the potential molecular pathways associated with CIP2A were screened using the phosphokinase array and identified through western blotting. Results CIP2A mRNA and protein levels were upregulated in CRC tissues compared to those of the corresponding normal tissues. It can be used as an independent prognostic indicator to determine overall survival (OS) and disease-free survival (DFS). Depletion of CIP2A substantially suppressed the growth of CRC cells and colony formation in vitro, and inhibited the growth of xenograft tumors in vivo. Additionally, the levels of CIP2A in the sera of patients with CRC were higher than those of the control subjects. Multivariate analyses revealed that the levels of CIP2A in the sera were not independent prognostic indicators in patients with CRC. Moreover, 10,058-F4 could effectively inhibit the growth of CRC cells in vitro, which could be correlated with an inhibition in the expressions of C-myc, CIP2A and its downstream regulatory anti-apoptotic proteins. Furthermore, the Human Phosphokinase Antibody Array was used to gain insights into the CIP2A-dependent intermediary signaling pathways. The results revealed that several signaling pathways were affected and the protein levels of p-p53 (S392), p-STAT5a (Y694), Cyclin D1, p-ERK1/2 and p-AKT (T308) had decreased in CIP2A-shRNA group based on the results of the western blot analysis. Conclusions CIP2A could promote the development of CRC cells and predict poor prognosis in patients with CRC, suggesting that it may serve as a potential prognostic marker and therapeutic target against CRC. Graphical abstract" @default.
- W3020785513 created "2020-05-01" @default.
- W3020785513 creator A5017541508 @default.
- W3020785513 creator A5035515939 @default.
- W3020785513 creator A5038801199 @default.
- W3020785513 creator A5043426999 @default.
- W3020785513 creator A5046457892 @default.
- W3020785513 creator A5061366775 @default.
- W3020785513 date "2020-04-22" @default.
- W3020785513 modified "2023-09-23" @default.
- W3020785513 title "Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer" @default.
- W3020785513 cites W1984118348 @default.
- W3020785513 cites W2011269145 @default.
- W3020785513 cites W2016594516 @default.
- W3020785513 cites W2021536610 @default.
- W3020785513 cites W2028901814 @default.
- W3020785513 cites W2032078306 @default.
- W3020785513 cites W2044809172 @default.
- W3020785513 cites W2046057377 @default.
- W3020785513 cites W2055404417 @default.
- W3020785513 cites W2068659362 @default.
- W3020785513 cites W2071572727 @default.
- W3020785513 cites W2074664629 @default.
- W3020785513 cites W2083459920 @default.
- W3020785513 cites W2086415754 @default.
- W3020785513 cites W2095978976 @default.
- W3020785513 cites W2107929060 @default.
- W3020785513 cites W2111186987 @default.
- W3020785513 cites W2111614147 @default.
- W3020785513 cites W2113343380 @default.
- W3020785513 cites W2113440726 @default.
- W3020785513 cites W2115859076 @default.
- W3020785513 cites W2120930686 @default.
- W3020785513 cites W2124960197 @default.
- W3020785513 cites W2139836283 @default.
- W3020785513 cites W2156118283 @default.
- W3020785513 cites W2160171104 @default.
- W3020785513 cites W2331670115 @default.
- W3020785513 cites W2334337082 @default.
- W3020785513 cites W2566580065 @default.
- W3020785513 cites W2568990594 @default.
- W3020785513 cites W2620018935 @default.
- W3020785513 cites W2762077288 @default.
- W3020785513 cites W2781525129 @default.
- W3020785513 cites W2781576266 @default.
- W3020785513 cites W2783813829 @default.
- W3020785513 cites W2910236521 @default.
- W3020785513 cites W2976277306 @default.
- W3020785513 cites W85869317 @default.
- W3020785513 doi "https://doi.org/10.1186/s12964-020-00545-6" @default.
- W3020785513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7178757" @default.
- W3020785513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32321509" @default.
- W3020785513 hasPublicationYear "2020" @default.
- W3020785513 type Work @default.
- W3020785513 sameAs 3020785513 @default.
- W3020785513 citedByCount "8" @default.
- W3020785513 countsByYear W30207855132020 @default.
- W3020785513 countsByYear W30207855132021 @default.
- W3020785513 countsByYear W30207855132022 @default.
- W3020785513 countsByYear W30207855132023 @default.
- W3020785513 crossrefType "journal-article" @default.
- W3020785513 hasAuthorship W3020785513A5017541508 @default.
- W3020785513 hasAuthorship W3020785513A5035515939 @default.
- W3020785513 hasAuthorship W3020785513A5038801199 @default.
- W3020785513 hasAuthorship W3020785513A5043426999 @default.
- W3020785513 hasAuthorship W3020785513A5046457892 @default.
- W3020785513 hasAuthorship W3020785513A5061366775 @default.
- W3020785513 hasBestOaLocation W30207855132 @default.
- W3020785513 hasConcept C104317684 @default.
- W3020785513 hasConcept C11960822 @default.
- W3020785513 hasConcept C121608353 @default.
- W3020785513 hasConcept C127561419 @default.
- W3020785513 hasConcept C178666793 @default.
- W3020785513 hasConcept C184235292 @default.
- W3020785513 hasConcept C203014093 @default.
- W3020785513 hasConcept C204232928 @default.
- W3020785513 hasConcept C22615655 @default.
- W3020785513 hasConcept C389152 @default.
- W3020785513 hasConcept C48023723 @default.
- W3020785513 hasConcept C502942594 @default.
- W3020785513 hasConcept C526805850 @default.
- W3020785513 hasConcept C54009773 @default.
- W3020785513 hasConcept C54355233 @default.
- W3020785513 hasConcept C62112901 @default.
- W3020785513 hasConcept C81885089 @default.
- W3020785513 hasConcept C85265743 @default.
- W3020785513 hasConcept C86803240 @default.
- W3020785513 hasConcept C95444343 @default.
- W3020785513 hasConceptScore W3020785513C104317684 @default.
- W3020785513 hasConceptScore W3020785513C11960822 @default.
- W3020785513 hasConceptScore W3020785513C121608353 @default.
- W3020785513 hasConceptScore W3020785513C127561419 @default.
- W3020785513 hasConceptScore W3020785513C178666793 @default.
- W3020785513 hasConceptScore W3020785513C184235292 @default.
- W3020785513 hasConceptScore W3020785513C203014093 @default.
- W3020785513 hasConceptScore W3020785513C204232928 @default.
- W3020785513 hasConceptScore W3020785513C22615655 @default.
- W3020785513 hasConceptScore W3020785513C389152 @default.
- W3020785513 hasConceptScore W3020785513C48023723 @default.
- W3020785513 hasConceptScore W3020785513C502942594 @default.